¡Ya estamos en ! Descubre más

Qiagen

QGEN

Capitalización de mercado USD 9526 M

46.13 USD

-0.04

0.09%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

46.13

0.00

0%

1 día

-0.09%

5 días

0.99%

1 mes

7.53%

3 meses

11.13%

6 meses

12.62%

En lo que va del año

2.08%

1 año

-4.16%

5 años

-16.52%

10 años

61.12%

Acerca de: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).

Empleados: 5,500

Atención médica Diagnósticos e investigación

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 23.8%

Neutral 66.7%

Negativo 9.5%

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) will bring together tuberculosis experts from around the world for the Global TB Clinical and Educational Summit from October 13-16 as a persistent disease burden and growing pressures on global health funding put renewed focus on tuberculosis prevention, screening and care. An estimated 10.7 million people worldwide developed tuberculosis in 2024 and nearly 1.2 million died from the d.

QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new artificial intelligence (AI) capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery Platform, which extends these capabilities int.

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

Zacks Investment Research

QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel

QGEN expands its U.S. QIAstat-Dx portfolio with an FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.

QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA). The new panel detects gram-negative bacteria and antibiotic resistance markers in about one hour, complementing the recently FDA-cleared QIAstat-Dx panel for gram-positive bacteria and fungi.

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAmini, a compact automated sample preparation system designed to give research laboratories a time-saving and cost-efficient alternative to processing samples by hand. QIAmini is designed primarily for academic laboratories and other research customers processing smaller sample batches that do not require larger automated systems. QIAGEN estimates the ad.

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

Zacks Investment Research

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET. Shareholders will be asked to vote on the appointment of Jonathan M. Pratt to the QIAGEN Managing Board after he joined QIAGEN as Chief Executive Officer on September 1, 2026. Subject to shareholder approval, Jon Pratt would join Roland Sackers, Chief Financial Officer, as the two me.

QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board

Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at 2026 Global Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Qiagen N.V. (QGEN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Zacks Investment Research

Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™